Recent advances in point-of-care testing for natriuretic peptides: potential impact on heart failure diagnosis and management

Expert Review of Molecular Diagnostics

Volumn 16, Issue 6, 2016, Pages 641-650

  Iwaz, James A ^a,b   Maisel, Alan S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

heart failure; Natriuretic peptides; point of care; triage

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; NATRIURETIC FACTOR; BIOLOGICAL MARKER;

CLINICAL EXAMINATION; HEALTH CARE COST; HEART FAILURE; HOSPITAL ADMISSION; HUMAN; MEDICATION THERAPY MANAGEMENT; PATIENT CARE; PHYSIOLOGY; POINT OF CARE TESTING; PROGNOSIS; REVIEW; BLOOD; MOLECULAR DIAGNOSIS; PROCEDURES; STANDARDS;

BIOMARKERS; HEART FAILURE; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; NATRIURETIC PEPTIDES; POINT-OF-CARE TESTING;

EID: 84961572599     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2016.1158105     Document Type: Review

References (67)

1. P.A.Heidenreich, N.M.Albert, L.A.Allen, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail [Internet]. 2013 May 24 [cited 2015 Apr 1]; 6(3): 606– 619. Available from: http://circheartfailure.ahajournals.org/content/early/2013/04/24/HHF.0b013e318291329a
2. A.Maisel, C.Mueller, R.Nowak, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea. results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol. Elsevier Inc.; 2010; 55(19): 2062– 2076.
3. S.-C.Lee, T.L.Stevens, S.M.Sandberg, et al. The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. J Card Fail [Internet]. 2002 Jun [cited 2015 Jun 22]; 8(3): 149– 154. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12140807
4. M.R.Cowie, A.D.Struthers, D.A.Wood, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet (London, England) [Internet]. 1997 Nov 8 [cited 2015 Jun 22]; 350(9088): 1349– 1353. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9365448
5. L.W.Stevenson The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA J Am Med Assoc [Internet]. American Medical Association; 1989 Feb 10 [cited 2015 Jun 22]; 261(6): 884. Available from: http://jama.jamanetwork.com/article.aspx?articleid=376284
6. A.S.Androne, K.Hryniewicz, A.Hudaihed, et al. Relation of unrecognized hypervolemia in chronic heart failure to clinical status, hemodynamics, and patient outcomes. Am J Cardiol [Internet]. 2004 May 15 [cited 2015 Jul 26]; 93(10): 1254– 1259. Available from: http://www.sciencedirect.com/science/article/pii/S0002914904002255
7. M.M.Müller, W.Hackl, A.Griesmacher. [Point-of-care-testing–the intensive care laboratory]. Anaesthesist [Internet]. 1999 Jan [cited 2016 Jan 21]; 48(1): 3– 8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10073241• This article discusses use of point-of-care testing, particularly use of INR, in patient homes.
8. E.Stürenburg, R.Junker. Point-of-care testing in microbiology: the advantages and disadvantages of immunochromatographic test strips. Dtsch ÄRzteblatt Int [Internet]. 2009 Jan [cited 2016 Jan 21]; 106(4); 48– 54. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2695304&tool=pmcentrez&rendertype=abstract
9. A.J.Francis, C.L.Martin. A practical example of PoCT working in the community. Clin Biochem Rev [Internet]. 2010 Aug [cited 2015 Nov 12]; 31(3); 93– 97. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2924129&tool=pmcentrez&rendertype=abstract
10. J.L.Januzzi, C.A.Camargo, S.Anwaruddin, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol [Internet]. Elsevier; 2005 Apr 15 [cited 2015 Jun 4]; 95(8): 948– 954. Available from: http://www.ajconline.org/article/S0002914905001153/fulltext
11. M.Weber, C.Hamm. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart [Internet]. 2006 Jun [cited 2015 Jun 22]; 92(6); 843– 849. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1860679&tool=pmcentrez&rendertype=abstract
12. P.Bettencourt, A.Azevedo, J.Pimenta, et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation [Internet]. 2004 Oct 12 [cited 2015 Apr 19]; 110(15): 2168– 2174. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15451800
13. B.C.Stein, R.I.Levin. Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease. Am Heart J [Internet]. Elsevier; 1998 May 5 [cited 2015 Jul 26]; 135(5): 914– 923. Available from: http://www.ahjonline.com/article/S0002870398700547/fulltext
14. Q.Dao, P.Krishnaswamy, R.Kazanegra, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol [Internet]. 2001 Feb [cited 2015 Jun 22]; 37(2): 379– 385. Available from: http://www.sciencedirect.com/science/article/pii/S0735109700011566
15. A.Y.-M.Wang, K.-N.Lai. Use of cardiac biomarkers in end-stage renal disease. J Am Soc Nephrol [Internet]. 2008 Sep 1 [cited 2015 Jun 22]; 19(9): 1643– 1652. Available from: http://jasn.asnjournals.org/content/19/9/1643.full
16. T.G.Yandle, A.M.Richards, M.G.Nicholls, et al. Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic peptide in man. Life Sci [Internet]. 1986 May [cited 2015 Jul 26]; 38(20); 1827– 1833. Available from: http://www.sciencedirect.com/science/article/pii/0024320586901372
17. R.Kazanegra, V.Cheng, A.Garcia, et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail [Internet]. 2001 Mar [cited 2015 Jun 22]; 7(1): 21– 29. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11264546
18. A.S.Maisel, P.Krishnaswamy, R.M.Nowak, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med [Internet]. 2002; 347(3): 161– 167. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12124404
19. M.Lainscak, S.Von Haehling, S.D.Anker. Natriuretic peptides and other biomarkers in chronic heart failure: from BNP, NT-proBNP, and MR-proANP to routine biochemical markers. Int J Cardiol [Internet]. 2009 Mar 6 [cited 2015 Jul 26]; 132(3): 303– 311. Available from: http://www.sciencedirect.com/science/article/pii/S0167527308013120
20. L.B.Daniels, A.S.Maisel. Natriuretic peptides. J Am Coll Cardiol. 2007; 50(25): 2357– 2368.
21. R.E.Hobbs, R.M.Mills. Endogenous B-type natriuretic peptide: a limb of the regulatory response to acutely decompensated heart failure. Clin Cardiol [Internet]. 2008 Sep [cited 2016 Jan 17]; 31(9); 407– 412. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18781599
22. M.A.Silver, A.Maisel, C.W.Yancy, et al. BNP consensus panel 2004: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail [Internet]. 2004 [ cited 2015 Jul 26]; 10(5 Suppl 3): 1– 30. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15604859
23. A.Bayés-Genís, J.Barallat, A.Galán, et al. Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients. J Am Coll Cardiol [Internet]. 2015 Feb 24 [cited 2016 Jan 17]; 65(7): 657– 665. Available from: http://content.onlinejacc.org/article.aspx?articleid=2119404
24. J.J.V.McMurray, M.Packer, A.S.Desai, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med [Internet]. 2014 Aug 30 [ cited 2014 Aug 30]; 371(11):140830040023009. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25176015
25. A.S.Jaffe. Unwinding the interaction of natriuretic peptides and neprilysin. J Am Coll Cardiol [Internet]. 2015 Feb 24 [ cited 2015 Dec 13]; 65(7): 666– 667. Available from: http://content.onlinejacc.org/article.aspx?articleID=2119409
26. K.N.Luckenbill, R.H.Christenson, A.S.Jaffe, et al. Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NT-proBNP assays: preliminary observations from the IFCC committee for standardization of markers of cardiac damage. Clin Chem [Internet]. 2008 Mar 1 [ cited 2016 Jan 17]; 54(3): 619– 621. Available from: http://www.clinchem.org/content/54/3/619.long
27. A.Maisel, C.Mueller, K.Adams, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail [Internet]. 2008 Sep [ cited 2015 Jun 2]; 10(9): 824– 839. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18760965
28. C.Mueller, A.Scholer, K.Laule-Kilian, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med [Internet]. 2004 Mar 12 [ cited 2015 Jun 29]; 350(7): 647– 654. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14960741
29. T.A.McDonagh, S.Holmer, I.Raymond, et al. NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies. Eur J Heart Fail [Internet]. 2004 Mar 20 [ cited 2015 Jun 29]; 6(3): 269– 273. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14987575
30. J.L.Januzzi, R.van Kimmenade, J.Lainchbury, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the international collaborative of NT-proBNP study. Eur Heart J [Internet]. 2006 Mar [ cited 2015 Jun 29]; 27(3): 330– 337. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16293638
31. A.Clerico, G.Iervasi, M.G.Del Chicca, et al. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. J Endocrinol Invest [Internet]. 1998 Mar [ cited 2015 Jun 24]; 21(3): 170– 179. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9591213
32. J.Koglin, S.Pehlivanli, M.Schwaiblmair, et al. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol [Internet]. 2001 Dec [cited 2015 Jun 28]; 38(7); 1934– 1941. Available from: http://www.sciencedirect.com/science/article/pii/S0735109701016722
33. D.Logeart, G.Thabut, P.Jourdain, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol [Internet]. 2004 Feb 18 [ cited 2015 Jun 22]; 43(4): 635– 641. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14975475
34. R.Valle, N.Aspromonte, L.Milani, et al. Optimizing fluid management in patients with acute decompensated heart failure (ADHF): the emerging role of combined measurement of body hydration status and brain natriuretic peptide (BNP) levels. Heart Fail Rev [Internet]. 2011 Nov [ cited 2015 May 18]; 16(6): 519– 529. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3151484&tool=pmcentrez&rendertype=abstract• This article discusses use of point-of-care laboratory values in the emergency room and found them to be a useful tool in triage of patients.
35. R.W.Troughton, C.M.Frampton, T.G.Yandle, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet (London, England) [Internet]. 2000 Apr 1 [ cited 2015 Jul 2]; 355(9210): 1126– 1130. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10791374
36. J.G.Lainchbury, R.W.Troughton, K.M.Strangman, et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-assisted treatment to lessen serial cardiac readmissions and death) trial. J Am Coll Cardiol [Internet]. 2009 Dec 29 [ cited 2015 Apr 19]; 55(1): 53– 60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20117364
37. S.Sanders-van Wijk, M.T.Maeder, F.Nietlispach, et al. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF. Circ Heart Fail [Internet]. 2014 Jan 18 [ cited 2015 Jun 1]; 7(1): 131– 139. Available from: http://circheartfailure.ahajournals.org/content/early/2013/12/18/CIRCHEARTFAILURE.113.000527
38. M.Pfisterer, P.Buser, H.Rickli, et al. BNP-guided vs symptom-guided heart failure therapy: the trial of intensified vs standard medical therapy in elderly patients with congestive heart failure (TIME-CHF) randomized trial. JAMA [Internet]. 2009 Jan 28 [ cited 2015 Jul 2]; 301(4): 383– 392. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19176440• Successful implementation of point-of-care testing requires a multidisciplinary approach.
39. T.J.Wang, M.G.Larson, D.Levy, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation [Internet]. 2004 Feb 10 [ cited 2015 May 27]; 109(5): 594– 600. Available from: http://circ.ahajournals.org/content/109/5/594.full. • This article compared point-of-care BNP testing (i-STAT) to standard lab assays and found that the precision of the i-STAT was poor; however, there was good agreement between i-STAT and lab values.
40. D.G.Krauser, D.M.Lloyd-Jones, C.U.Chae, et al. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP investigation of dyspnea in the emergency department (PRIDE) substudy. Am Heart J [Internet]. 2005 Apr [ cited 2015 Jul 2]; 149(4): 744– 750. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15990762
41. T.B.Horwich, M.A.Hamilton, G.C.Fonarow. B-type natriuretic peptide levels in obese patients with advanced heart failure. J Am Coll Cardiol [Internet]. 2006 Jan 3 [ cited 2015 Jul 2]; 47(1): 85– 90. Available from: http://content.onlinejacc.org/article.aspx?articleid=1137150• Potential disadvantages of point-of-care testing include cost and quality and regulatory issues.
42. A.Bayes-Genis, D.M.Lloyd-Jones, R.R.J.van Kimmenade, et al. Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea. Arch Intern Med [Internet]. American Medical Association; 2007 Feb 26 [ cited 2015 Jul 2]; 167(4): 400– 407. Available from http://archinte.jamanetwork.com/article.aspx?articleid=411764• This article looked at point-of-care BNP testing in the emergency room and found that point-of-care testing may be more beneficial for indeterminate cases of heart failure.
43. T.Tsutamoto, A.Wada, H.Sakai, et al. Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure. J Am Coll Cardiol [Internet]. 2006 Feb 7 [ cited 2015 May 17]; 47(3): 582– 586. Available from: http://content.onlinejacc.org/article.aspx?articleid=1137251
44. S.Anwaruddin, D.M.Lloyd-Jones, A.Baggish, et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP investigation of dyspnea in the emergency department (PRIDE) study. J Am Coll Cardiol [Internet]. 2006 Jan 3 [ cited 2015 Jul 2]; 47(1): 91– 97. Available from: http://www.sciencedirect.com/science/article/pii/S0735109705023521
45. J.A.de Lemos, D.A.Morrow, J.H.Bentley, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med [Internet]. 2001 Oct 4 [ cited 2015 Jun 22]; 345(14): 1014– 1021. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11586953
46. A.A.Hussein, W.I.Saliba, D.O.Martin, et al. Plasma B-type natriuretic peptide levels and recurrent arrhythmia after successful ablation of lone atrial fibrillation. Circulation [Internet]. 2011 May 17 [ cited 2015 Jun 22]; 123(19): 2077– 2082. Available from: http://circ.ahajournals.org/content/123/19/2077.full
47. N.Kucher, S.Z.Goldhaber. Cardiac biomarkers for risk stratification of patients with acute pulmonary embolism. Circulation [Internet]. 2003 Nov 4 [ cited 2015 Jun 22]; 108(18): 2191– 2194. Available from: http://circ.ahajournals.org/content/108/18/2191.full
48. P.Pruszczyk, M.Kostrubiec, A.Bochowicz, et al. N-terminal pro-brain natriuretic peptide in patients with acute pulmonary embolism. Eur Respir J [Internet]. 2003 Oct 1 [ cited 2015 Jun 22]; 22(4): 649– 653. Available from: http://erj.ersjournals.com/content/22/4/649.long
49. N.Nagaya, T.Nishikimi, Y.Okano, et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol [Internet]. 1998 Jan [ cited 2015 Jul 6]; 31(1): 202– 208. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9426041
50. G.Casals, J.Ros, A.Sionis, et al. Hypoxia induces B-type natriuretic peptide release in cell lines derived from human cardiomyocytes. Am J Physiol Heart Circ Physiol [Internet]. 2009 Aug 1 [ cited 2015 Jun 22]; 297(2): H550– H555. Available from: http://ajpheart.physiology.org/content/297/2/H550.full
51. W.V.Tamborlane, R.W.Beck, B.W.Bode, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med [Internet]. 2008 Oct 2 [ cited 2015 Nov 12]; 359(14): 1464– 1476. Available from: http://europepmc.org/abstract/med/18779236
52. A.J.Macnab, G.Grant, K.Stevens, et al. Cost: benefit of point-of-care blood gas analysis vs. laboratory measurement during stabilization prior to transport. Prehosp Disaster Med [Internet]. 2003 [ cited 2015 Nov 12]; 18(1): 24– 28. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14694897
53. O.A.Soremekun, E.M.Datner, S.Banh, et al. Utility of point-of-care testing in ED triage. Am J Emerg Med [Internet]. 2013 Feb [cited 2015 Nov 12]; 31(2); 291– 296. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23083886
54. E.S.Christenson, P.O.Collinson, C.R.Defilippi, et al. Heart failure biomarkers at point-of-care: current utilization and future potential. Expert Rev Mol Diagn [Internet]. 2014 Mar [cited 2016 Jan 21]; 14(2); 185– 197. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24524847
55. A.S.Maisel, J.Koon, P.Krishnaswamy, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J [Internet]. 2001 Mar [ cited 2015 Jun 24]; 141(3): 367– 374. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11231433
56. A.Maisel, D.Barnard, B.Jaski, et al. Primary results of the HABIT trial (heart failure assessment with BNP in the home). J Am Coll Cardiol [Internet]. 2013 Apr 23 [ cited 2016 Jan 1]; 61(16): 1726– 1735. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23500322
57. A.S.Maisel, K.S.Shah, D.Barnard, et al. How B-type natriuretic peptide (BNP) and body weight changes vary in heart failure with preserved ejection fraction compared with reduced ejection fraction: secondary results of the HABIT (HF assessment with BNP in the home) trial. J Card Fail [Internet]. 2015 Oct 31 [ cited 2015 Nov 6]. Available from http://www.ncbi.nlm.nih.gov/pubmed/26433086
58. C.Zugck, M.Nelles, H.A.Katus, et al. Multicentre evaluation of a new point-of-care test for the determination of NT-proBNP in whole blood. Clin Chem Lab Med [Internet]. 2006 Jan [ cited 2015 Nov 12]; 44(10): 1269– 1277. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17032141
59. R.Ro, H.C.Thode, M.Taylor, et al. Comparison of the diagnostic characteristics of two B-type natriuretic peptide point-of-care devices. J Emerg Med [Internet]. 2011 Dec [cited 2015 Sep 28]; 41(6); 661– 667. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21620610
60. J.M.Kosowsky, C.Weiner, A.A.Aronson, et al. Impact of point-of-care B-type natriuretic peptide (BNP) measurement on medical decision-making for older emergency department patients with dyspnea. J Emerg Med [Internet]. 2006 Aug [cited 2015 Nov 12]; 31(2); 147– 150. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17044575
61. J.H.Nichols, S.S.Poe. Quality assurance, practical management, and outcomes of point-of-care testing: laboratory perspectives, part I. Clin Lab Manage Rev [Internet]. 1999 [ cited 2015 Nov 12]; 13(6): 341– 350. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10747660
62. K.Shah, G.J.Terracciano, K.Jiang, et al. Comparability of results between point-of-care and automated instruments to measure B-type natriuretic peptide. West J Emerg Med [Internet]. 2010 Feb [cited 2015 Nov 12]; 11(1); 44– 48. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2850853&tool=pmcentrez&rendertype=abstract
63. C.Prontera, S.Masotti, M.Franzini, et al. Comparison between BNP values measured in capillary blood samples with a POCT method and those measured in plasma venous samples with an automated platform. Clin Chem Lab Med [Internet]. 2015 Apr [ cited 2016 Jan 21]; 53(5): e125– e127. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25372724
64. A.Clerico, C.Passino, M.Franzini, et al. Cardiac biomarker testing in the clinical laboratory: where do we stand? General overview of the methodology with special emphasis on natriuretic peptides. Clin Chim Acta [Internet]. 2015 Mar 30 [ cited 2015 Dec 13]; 443: 17– 24. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24937843
65. C.Prontera, M.Zaninotto, S.Giovannini, et al. Proficiency testing project for brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP (NT-proBNP) immunoassays: the CardioOrmocheck study. Clin Chem Lab Med [Internet]. 2009 Jan [ cited 2016 Jan 25]; 47(6): 762– 768. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19402791
66. J.S.Nosanchuk, R.Keefner. Cost analysis of point-of-care laboratory testing in a community hospital. Am J Clin Pathol [Internet]. 1995 103(2); 240– 243. Feb [cited 2015 Nov 12]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/7856570
67. G.J.Kost. The Laboratory-Clinical Interface *. CHEST J [Internet]. American College of Chest Physicians; 1999 Apr 1 [ cited 2015 Nov 12]; 115(4): 1140– 1154. Available from: http://journal.publications.chestnet.org/article.aspx?articleid=1077113#PotentialAdvantagesandDisadvantages